18Fluorodeoxyglucose-positron emission tomography/computed tomography features of suspected solitary pulmonary lesions in breast cancer patients following previous curative treatment

Lei Zhu1*, Haiman Bian2,3*, Lieming Yang4, Jianjing Liu1, Wei Chen1, Xiaofeng Li1, Jian Wang1, Xiuyu Song1, Dong Dai1, Zhaoxiang Ye2, Wengui Xu1 & Xiaozhou Yu1

1 Department of Molecular Imaging and Nuclear Medicine, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
2 Department of Radiology, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
3 Department of Radiology, Tianjin 4th Centre Hospital, Tianjin, China
4 Department of Cardiovascular Surgery, Tianjin Medical University General Hospital, Tianjin, China

Keywords
18Fluorodeoxyglucose-positron emission tomography/computed tomography; breast cancer metastasis; lung cancer; solitary pulmonary lesion.

Correspondence
Zhaoxiang Ye, Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Tianjin’s Clinical Research Center for Cancer, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Tel: +86 22 2334 0123
Fax: +86 22 2353 7796
Email: yezhaoxiang@163.com

Wengui Xu, Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Tianjin’s Clinical Research Center for Cancer, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
Tel: +86 22 2334 0123
Fax: +86 22 2353 7796
Email: wenguixy@163.com

Xiaozhou Yu, Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Tianjin’s Clinical

Abstract

Background: Differentiating pulmonary metastasis from primary lung cancer can be challenging in patients with breast malignancy. This study aimed to characterize the imaging features of 18fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) for distinguishing between these diseases.

Methods: We enrolled 52 patients who received curative treatment for breast cancer but later presented with suspected solitary pulmonary lesions (SPLs) and subsequently underwent 18F-FDG-PET/CT to investigate.

Results: Subsolid lesions, ill-defined borders, lung lesions with negative maximum standardized uptake value, and lesions without 18F-FDG-PET/CT-diagnosed hilar and/or mediastinal lymph nodes and pleural metastases were more likely to be associated with primary lung cancer.

Conclusions: CT border, FDG uptake, hilar and/or mediastinal lymph node metastasis, and pleural metastasis are potential markers for diagnosis.
Introduction

According to Cancer Statistics 2017, breast cancer is the most commonly diagnosed and the second-leading cause of cancer death among women, contributing to an estimated 252,720 new cases and 40,610 deaths per year in the United States.1 Approximately 20% of these patients present with distant metastasis at diagnosis that accounts for a poor prognosis and lower quality of life. Indeed, the lung is one of the most common sites targeted by metastatic cancer cells.2

Solitary pulmonary metastasis after curative treatment for breast cancer is rare in patients with breast malignancy. Although it is not difficult to detect lung lesions with advanced imaging technology, differentiating pulmonary metastasis from primary lung cancer and other benign conditions can be challenging after curative treatment for breast cancer.2–5

Approximately 12% of breast cancer patients show solitary pulmonary lesions (SPLs)6 that mimic primary lung cancer, which is not concordant with the fact that pulmonary metastasis usually exhibits a multiple lesion pattern in various malignancies.7 On the other hand, many studies have reported that a second primary tumor, such as lung cancer, is highly likely to be a concurrent condition in breast cancer patients.2,4,8 An accurate diagnosis will also have a significant impact on future treatment plans,5 as surgical resection is more appropriate for primary lung cancer patients, while pulmonary metastasis requires systemic therapy.2,9 As a result, it is essential to make a precise diagnosis once SPLs are detected in women who have received prior curative treatment for breast cancer.3–5

18Fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT), a molecular imaging strategy, has been widely applied in oncology in recent decades.10–14 Current international guidelines suggest that suspected pulmonary metastasis in breast cancer is an indication for an 18F-FDG-PET/CT scan, which helps to achieve accurate diagnosis and restaging for subsequent treatment.15–18 For patients with clinically suspected lung cancer or pulmonary lesions that cannot be confidently diagnosed, 18F-FDG-PET/CT is also highly recommended.19–21

Recent studies have investigated the potential differences in clinical characteristics among breast cancer patients with SPLs2–5,22–25 however, the 18F-FDG-PET/CT features in this population have not been well researched. In this retrospective study, we characterize the imaging features of 18F-FDG-PET/CT to differentiate highly suspected SPLs resulting from breast cancer metastasis with primary lung cancer among breast cancer patients who received prior curative treatment, as well as those with benign pathology.

Methods

Participants

Patients who underwent 18F-FDG-PET/CT scanning at the Tianjin Medical University Cancer Institute and Hospital between June 2009 and October 2016 were retrospectively selected. The inclusion criteria were: (i) female patients who previously received curative treatment for breast cancer (surgery with or without adjuvant therapy and radiotherapy); (ii) patients who underwent 18F-FDG-PET/CT scanning to investigate a newly found suspected SPL on CT after initial treatment, and the minimum axial diameter of the lung lesion was 8 mm;26 and (iii) a pathological report of the SPLs was available (immunohistochemistry results were required; however in cases with benign lung lesions, a long-term follow-up result showing disease remission without treatment was also acceptable). The exclusion criteria were: (i) patients with a history of disease
maximum standardized uptake value (SUVmax) threshold cally marked using an isocontour method with a tion (< 70 Hu). A volume of interest (VOI) was automati-
mediastinal blood pool uptake), and visually lower attenua-
ter larger than 1 cm, increased uptake of FDG (higher than 
nant according to the following criteria: short-axis diame-
Hilar and mediastinal adenopathy was diagnosed as malig-
Healthcare). Suspicious cases were resolved by discussion.
The images on an Advantage Workstation (Version 4.4, GE
1.25 mm was also obtained.
reconstructed with iterative algorithms. A non-contrast CT
interval, 5 or 3.75 mm. Attenuation-corrected PET images
120 kV; slice thickness, 5 or 3.75 mm; and reconstruction
18F-FDG-PET/CT scanning was conducted using a Discov-
tomography (PET/CT) scanning and image
Positron emission tomography/computed tomography (PET/CT) scanning and image interpretation
18F-FDG-PET/CT scanning was conducted using a Discovery ST PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Patients were required to fast for six hours before the scan. Serum glucose was closely monitored before the intravenous injection of 18F-FDG. The administered activity of the radiotracer was 4.1–4.8 MBq (0.11–0.13 mCi) per kilogram of body weight. Scanning was conducted from the mid thigh to the vertex approximately one hour after 18F-FDG injection. CT scanning was performed with the following parameters: current, 120–170 mA; voltage, 120 kV; slice thickness, 5 or 3.75 mm; and reconstruction interval, 5 or 3.75 mm. Attenuation-corrected PET images were gathered at two minutes per frame and were reconstructed with iterative algorithms. A non-contrast CT scan targeted at the lung nodule with a slice thickness of 1.25 mm was also obtained.
Three senior radiologists in nuclear medicine reviewed the images on an Advantage Workstation (Version 4.4, GE Healthcare). Suspicious cases were resolved by discussion. Hilar and mediastinal adenopathy was diagnosed as malignant according to the following criteria: short-axis diameter larger than 1 cm, increased uptake of FDG (higher than mediastinal blood pool uptake), and visually lower attenuation (< 70 Hu). A volume of interest (VOI) was automatically marked using an isocontour method with a fixed maximum standardized uptake value (SUVmax) threshold of 2.5.
The following metabolic parameters were measured: the SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the lung lesion; and the SUVmax, MTV, and TLG of whole body lesions. SUVs were automatically generated via software using the following equation: 
\[ \text{SUV} = \frac{\text{radioactivity concentration}}{\text{injected activity/body weight}} \]
The MTVs were the volume of VOIs. TLGs were calculated by multiplying the average SUV by the MTV of VOIs.

Statistical analysis
Categorical variables were recorded as numbers and percentages. Continuous variables were recorded as median (range) or mean ± standard deviation, depending on the distribution of data. Variable comparisons were performed using the independent Student’s t, Mann–Whitney U, or chi-squared test, as appropriate. Logistic regression was used for multivariate analyses. \( P < 0.05 \) was considered statistically significant. All statistical data were analyzed using SPSS version 17.0.

Results

Patient characteristics
A total of 52 patients met the inclusion criteria and were included in this study. None of the patients had cancer in situ or had undergone breast conserving surgery or neoadjuvant treatment. The clinicopathological characteristics of the study population are shown in Table 1.

Imaging and pathology
On 18F-FDG-PET/CT, the lung lesion was 18F-FDG avid in 41 (78.8%) patients, with a SUVmax of > 2.5. The mean SUVmax in all patients was 7.8 ± 6.1 (including both positive and negative SPLs). In 14 (26.9%) patients, additional potentially malignant lesions were discovered on 18F-FDG-PET/CT. The detected metastases were as follows: hilar and/or mediastinal lymph node (LN, 14/14, 100.0%); pleural (4/14, 28.6%); bone (4/14, 28.6%); cervical and/or supraclavicular (3/14, 21.4%); brain (2/14, 14.3%); liver (2/14, 14.3%); and axillary (1/14, 7.1%). Thirty of the 52 patients also underwent hilar and/or mediastinal LN dissection. The sensitivity, specificity, and accuracy of detecting hilar and/or mediastinal LN metastasis in these patients were 55.5%, 100%, and 86.7%, respectively.

Among the 52 patients, the confirmed pathological results of the lung lesions were as follows: pulmonary metastasis (22/52, 42.3%); primary lung cancer (22/52, 42.3%); and benign pulmonary disease (8/52, 15.4%). Of the 22 patients with pulmonary metastasis, 1 (4.5%) was FDG-negative. Of the 22 patients with primary lung cancer, 6 (27.3%) were FDG-negative with the following pathologies: adenocarcinoma (18/22, 81.8%), adenosquamous carcinoma (2/22, 9.1%), squamous carcinoma (1/22, 4.5%), and small cell lung cancer (1/22, 4.5%). Typical presentations of FDG-positive cases are shown in Figure 1. Among the eight patients with benign disease, four were FDG-negative (50%). In these eight patients, two were identified with fibroma and focal fibrosis combined with lymphocyte infiltration, respectively; two had tuberculosis; and two had sclerosing hemangioma. The remaining two patients did not undergo pathological examination but long-term follow-up data showed that their lung lesions disappeared without antitumor treatment (Fig 2).
CT characteristics were also evaluated to investigate their impact on the accuracy of diagnoses (Table 3). Of the 22 patients with pulmonary metastasis, only 1 patient (4.5%) had a subsolid lesion, which was a significantly lower incidence compared to patients with primary lung cancer (27.3%; P = 0.04). In addition, patients with primary lung cancer were more likely to present with ill-defined lesions compared to those with pulmonary metastasis (78.6% vs. 50%; P = 0.001). Other CT characteristics were not significantly different between the two patient groups.

As shown in Table 4, SUV$_{\text{max}}$, MTV, and TLG of both lung lesions and whole-body malignant lesions (diagnosis of $^{18}$F-FDG-PET/CT) were included in the analysis. We found that when using a traditional cutoff point of 2.5, the positivity or negativity of SUV$_{\text{max}}$ is a significant diagnostic factor. Most patients with negative SUV$_{\text{max}}$ results had primary lung cancer (6/7, 85.7%) (P = 0.04). In addition, the SUV$_{\text{max}}$ of whole-body lesions seemed a little higher in patients with pulmonary metastasis (11.1 ± 6.0) compared to those with primary lung cancer (7.8 ± 5.7), although the difference was not statistically significant (P = 0.07).

We found the distribution of metastasis could help to differentiate primary lung cancer and pulmonary metastasis. The hilar and/or mediastinal LN was a significant factor. However, unexpectedly, there were far more pulmonary metastasis patients with hilar and/or mediastinal LNs (diagnosis via $^{18}$F-FDG-PET/CT) than patients with primary lung cancer (P = 0.01). Pleural metastasis was also a risk factor of pulmonary metastasis (P = 0.04). Indeed, we found that all four patients with pleural metastasis discovered via $^{18}$F-FDG-PET/CT were from the pulmonary metastasis group.

Multivariate analysis revealed that a CT border characteristic was the only significant predictor for pulmonary metastasis after breast cancer curative treatment, unlike other factors, such as lesion type, FDG uptake of the lung lesion, and metastasis pattern (Table 5).

**Discussion**

In this work, we focused on a small group of female breast cancer patients who received curative treatment and then developed SPLs. Our data revealed that among these patients, the chance of developing new primary lung cancer and pulmonary metastasis were similar. In these two groups of patients, subsolid lesions, ill-defined border lesions, lesions with negative FDG uptake, and SPLs without $^{18}$F-FDG-PET/CT diagnosed hilar and/or mediastinal LNs or pleural metastasis were more likely to be associated with primary lung cancer than with pulmonary metastasis. Of these diagnostic factors, lesion border status was found to be an independent predictor.
SPLs after curative treatment for breast cancer, which mimic primary lung cancer and pulmonary metastasis and require significantly different management, are a rare condition that is seldom accurately diagnosed.2,3,9,27–30 In particular, careful observation by an experienced pathologist and immunohistochemistry staining might not be sufficient to differentiate primary lung cancer (especially adenocarcinoma) from pulmonary metastasis of breast cancer. A few previous studies have reported how to make a diagnosis using regular radiological methods. The results varied because of small sample sizes and different study methods.2–5,22–25 To the best of our knowledge, our research is the first to describe the imaging features of 18F-FDG-PET/CT for differentiating highly suspected SPLs resulting from breast cancer metastasis and primary lung cancer among breast cancer patients who have received prior curative treatment.

Because primary lung cancer and pulmonary metastasis after breast cancer curative treatment are both uncommon in real clinical settings, there is no international guideline available in regard to differential diagnosis.18F-FDG-PET/CT is a powerful radiological method for detecting primary lung cancer and breast cancer metastasis.15–21 Therefore, based on current research data and general guidelines for both lung cancer and breast cancer diagnosis, an 18F-FDG-PET/CT scan is an appropriate management option.

Figure 1 18Fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) images of primary lung cancer and pulmonary metastasis. (a-d) A 54-year-old woman underwent surgery for stage II breast cancer followed by adjuvant chemotherapy. 18F-FDG-PET/CT revealed a suspected solitary pulmonary lesion (SPL) (with a maximum standardized uptake value [SUV\text{max}] of 4.83) 181 months after surgery. Hilar and mediastinal lymph nodes (LNs) were also positive. The patient underwent lung biopsy and mediastinoscopy surgery, which confirmed primary lung adenocarcinoma combined with multiple hilar and mediastinal LN metastases. (e-h) A 60-year-old woman underwent surgery for stage II breast cancer followed by adjuvant chemotherapy. PET/CT revealed a suspected SPL (SUV\text{max} of 8.74) 259 months after surgery. Hilar and mediastinal LNs were also positive. Later surgery confirmed pulmonary metastasis combined with multiple hilar and mediastinal LN metastases from breast cancer. All lesions are marked with arrows.
According to our data, approximately 15% of all patients were false positive cases. Similar results have been reported in other studies. Thus, we should note that the proportion of benign patients is not low, even in these patients. In patients with definite malignant pulmonary lesions, the proportions of primary lung cancer and pulmonary metastasis were similar in this study. This finding could assist physicians in their clinical work and is in accordance with the results of previous research. We anticipated that older patients with advanced breast cancer and a shorter disease-free interval (DFI) were more likely to have pulmonary metastasis. Interestingly, none of these parameters was a significant predictor. A few studies have indicated that age could be a significant factor for differential diagnosis, as the incidence peak of breast cancer presents at a younger age than lung cancer. In this work, a similar trend was observed, however the difference was not significant. It is well known that most breast cancer recurrence occurs during the first five years since initial treatment. Hence, it is logical that patients with longer DFI are less likely to have metastasis. However, an adverse finding was revealed in our study (as shown in Table 2): the mean DFI of the metastasis group was approximately seven years, and therefore these tumors were “indolent metastases.” We suggest that as a seven-year period is already beyond the common...
surveillance period for breast cancer metastasis, prior data could be biased because of a lack of follow-up.

Common CT characteristics were included in our analysis. We found that both lesion type and border were significant predictors of primary lung cancer. It is well known that a radiological subsolid pulmonary lesion is one of the typical characteristics of primary lung adenocarcinoma, even though it could also be pulmonary metastasis (in rare cases), such as pulmonary metastasis with lepidic growth. When examining 18F-FDG-PET/CT characteristics, the SUVmax cutoff point of 2.5 was a significant predictor in multivariate analysis. Most FDG-negative lesions were primary lung cancer and all of these patients had adenocarcinoma with subsolid radiological presentation. The value of metabolic parameters, such as SUVmax, MTV, and TLG, has a limited diagnostic effect.

Axillary LNs, the lung, bone, and the liver are the most common sites of metastasis in breast cancer patients, while metastasis to hilar and mediastinal LNs, bone, the adrenal gland, liver, and brain are common in primary lung cancer. Our data revealed that hilar and/or mediastinal LN metastasis was a significant predictor of pulmonary metastasis, which is contradictory to the traditional perspective. 18F-FDG-PET/CT is reported to have a sensitivity of 50–79% and a specificity of 72–94% for the diagnosis of lung cancer mediastinal LN metastasis. However, no prior data is available regarding the use of the same imaging strategy for a diagnosis of breast cancer mediastinal LN metastasis. Our results indicated that 18F-FDG-PET/CT has a high level of specificity and accuracy for detecting hilar/mediastinal metastasis. Although such metastasis could not be definitively confirmed by 18F-FDG-PET/CT, it is the most applicable and precise method available compared to a pathological examination. Therefore, metastasis from breast cancer should first be considered once suspected hilar and/or mediastinal LNs are found on 18F-FDG-PET/CT among the target population. 18F-FDG-PET/CT-detected pleural metastasis was also a significant diagnostic factor. Indeed, all four patients who presented

### Table 2 Clinicopathological differences between patients with primary lung cancer and pulmonary metastasis

| Variable                  | Primary lung cancer | Pulmonary metastasis | P       |
|---------------------------|---------------------|----------------------|---------|
| Age, median (range) (years) | 60 (39–73)          | 55 (38–68)           | 0.17    |
| BMI, median (range) (kg/m²) | 25.2 (18.4–33.7)    | 25.0 (17.9–30.1)     | 0.69    |
| Smoking history            | Yes 1               | 1                    |         |
|                           | No 21               | 21                   |         |
| TNM stage of breast cancer| I 8                 | 6                    | 0.66    |
|                           | II 11               | 14                   |         |
|                           | III 3               | 2                    |         |
| Treatment of breast cancer| Adjuvant chemotherapy| 1.00                |         |
|                           | Yes 21              | 20                   |         |
|                           | No 1                | 2                    |         |
|                           | Adjuvant radiotherapy| 0.54                |         |
|                           | Yes 8               | 10                   |         |
|                           | No 14               | 12                   |         |
| DFI, months               | 105.4 ± 81.5        | 81.4 ± 65.7          | 0.29    |
| DFI Cutoff point of 5 and 10| > 10 years 7        | 4                    | 0.41    |
|                           | 5–10 years 8        | 7                    |         |
|                           | < 5 years 7         | 11                   |         |
| Cutoff point of 15        | < 15 years 17       | 20                   | 0.22    |
|                           | > 15 years 5        | 2                    |         |
| Laterality of breast cancer| Left 7              | 12                   | 0.13    |
|                           | Right 15            | 10                   |         |
| Laterality of pulmonary lesion | Left 9              | 10                   | 0.76    |
|                           | Right 13            | 12                   |         |
| Laterality between breast cancer and pulmonary lesion | Ipsilateral 10 | 8 | 0.54 |
|                           | Contralateral 12    | 14                   |         |

BMI, body mass index; DFI, disease-free interval; TNM, tumor node metastasis.

### Table 3 Computed tomography characteristics of lung lesions in patients with primary lung cancer and lung metastasis

| Variable                  | Primary lung cancer | Pulmonary metastasis | P       |
|---------------------------|---------------------|----------------------|---------|
| Size of pulmonary lesion, cm |                    |                      |         |
| Maximum axial diameter     | 2.3 ± 0.8           | 2.3 ± 1.2            | 0.94    |
| Minimum axial diameter     | 1.8 ± 0.7           | 1.8 ± 1.0            | 0.75    |
| Lesion type                | Solid 16            | 21                   | 0.04    |
|                           | Subsolid 6          | 1                    |         |
| Border                    | Well-defined 3      | 11                   | 0.01    |
|                           | Ill-defined 19      | 11                   |         |
| Lobulation                | Yes 18              | 18                   |         |
|                           | No 4                | 4                    |         |
| Spiculation               | Yes 17              | 15                   | 0.50    |
|                           | No 5                | 7                    |         |
| Pleural indentation        | Yes 11              | 9                    | 0.55    |
|                           | No 11               | 13                   |         |
| Cavity                    | Yes 4               | 2                    | 0.66    |
|                           | No 18               | 20                   |         |
| Location of pulmonary lesion | Peripheral 18       | 21                   | 0.34    |
|                           | Central 4           | 1                    |         |
with pleural metastasis were finally diagnosed with pulmonary metastasis. This result was also contradictory to usual clinical practice, as pleural metastasis is more common in lung cancer patients.39

There are some limitations to this study. Firstly, because of the retrospective design, missing data was inevitable, as patients with multiple distant metastases usually refused biopsy and thus were subsequently lost to follow-up. Secondly, patients who underwent breast conservation surgery and neoadjuvant therapy were not observed in this work, indicating that the enrolled population did not generally represent the target population and thus there was selection bias. Finally, the status of important pathological parameters – such as ER, PR, HER2, and Ki-67 – were not available for this research because of the long enrollment period and significant difficulties in retrieving accurate data.

In conclusion, 18F-FDG-PET/CT features are useful to predict pulmonary metastasis in breast cancer patients who have received prior curative treatment. Among them, CT border status, FDG uptake of the lung lesion, hilar and/or mediastinal LN metastasis, and pleural metastasis are potential imaging markers for accurate diagnoses.

### Acknowledgments

This work was supported by grants from National Natural Science Foundation of China (81601377, 81501984), the Tianjin Science and Technology Fund (18PTZWHZ00100, H2018206600), the Tianjin Natural Science Fund (16JCZDJC35200, 17JCYBJC25100), and the Science & Technology Development Fund of Tianjin Education Commission for Higher Education (2018KJ057, 2018KJ061).

### Disclosure

No authors report any conflict of interest.

---

**Table 4** PET/CT characteristics of lung lesions in patients with primary lung cancer and pulmonary metastasis

| Variable                              | Primary lung cancer | Pulmonary metastasis | P     |
|---------------------------------------|---------------------|---------------------|-------|
| SUVmax of pulmonary lesion            | 7.1 ± 5.7           | 10.2 ± 6.3          | 0.10  |
| FDG uptake of pulmonary lesion        |                     |                     | 0.04  |
| Positive                              | 16                  | 21                  |       |
| Negative                              | 6                   | 1                   |       |
| SUVmax of whole lesions               | 7.8 ± 5.7           | 11.1 ± 6.0          | 0.07  |
| MTV of pulmonary lesion (cm³)         | 8.0 ± 11.7          | 12.5 ± 18.7         | 0.34  |
| MTV of whole lesions (cm³)            | 14.8 ± 27.0         | 151.9 ± 573.3       | 0.27  |
| TLG of pulmonary lesion, median (range)| 17.2 (0.0–351.9) | 27.2 (0.0–532.7) | 0.29  |
| TLG of whole lesions                  | 70.0 ± 128.7        | 705.0 ± 2529.3      | 0.25  |
| Metastasis detected on PET/CT          |                     |                     | 0.01  |
| Hilar and/or mediastinal LN metastasis|                     |                     |       |
| Yes                                   | 3                   | 11                  |       |
| No                                    | 19                  | 11                  |       |
| Skeletal metastasis                   |                     |                     | 0.60  |
| Yes                                   | 1                   | 3                   |       |
| No                                    | 21                  | 19                  |       |
| Axillary metastasis                   |                     |                     | 1.00  |
| Yes                                   | 0                   | 1                   |       |
| No                                    | 22                  | 21                  |       |
| Brain metastasis                      |                     |                     | 1.00  |
| Yes                                   | 1                   | 1                   |       |
| No                                    | 21                  | 21                  |       |
| Pleural metastasis                    |                     |                     | 0.04  |
| Yes                                   | 0                   | 4                   |       |
| No                                    | 22                  | 18                  |       |
| Cervical and/or supraclavicular metastasis |   |                     | 1.00  |
| Yes                                   | 2                   | 1                   |       |
| No                                    | 20                  | 21                  |       |
| Liver metastasis                      |                     |                     | 0.47  |
| Yes                                   | 0                   | 2                   |       |
| No                                    | 22                  | 20                  |       |

FDG, 18fluorodeoxyglucose; LN, lymph node; MTV, metabolic tumor volume; PET/CT, positron emission tomography/computed tomography; SUVmax, maximum standardized uptake value; TLG, total lesion glycolysis.

**Table 5** Multivariate analysis in patients with pulmonary metastasis after curative treatment for breast cancer

| Variable                              | OR (95% CI) | P     |
|---------------------------------------|-------------|-------|
| Lesion type                           | 0.83 (0.03, 23.30) | 0.91  |
| Solid                                 |             |       |
| Subsolid                              |             |       |
| Border                                | 8.76 (1.37, 56.21) | 0.02  |
| Well-defined                          |             |       |
| Ill-defined                            |             |       |
| FDG uptake of pulmonary lesion        | 0.14 (< 0.01, 4.31) | 0.26  |
| Positive                              |             |       |
| Negative                              |             |       |
| Metastasis detected on PET/CT         |             |       |
| Hilar and/or mediastinal LN metastasis| 4.50 (0.79, 25.71) | 0.09  |
| Yes                                   |             |       |
| No                                    |             |       |
| Pleural metastasis                    | < 0.01 (0.00, −) | 1.00  |
| Yes                                   |             |       |
| No                                    |             |       |

CI, confidence interval; FDG, 18fluorodeoxyglucose; LN, lymph node; OR, odds ratio; PET/CT, positron emission tomography/computed tomography.
References

1 Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67 (1): 7–30.
2 Rena O, Papalia E, Ruffini E et al. The role of surgery in the management of solitary pulmonary nodule in breast cancer patients. Eur J Surg Oncol 2007; 33 (5): 546–50.
3 Kinoshita T, Yoshida J, Ishii G et al. The availability of pre- and intraoperative evaluation of a solitary pulmonary nodule in breast cancer patients. Ann Thorac Cardiovasc Surg 2015; 21 (1): 31–6.
4 Okasaka T, Usami N, Mitsudomi T, Yatabe Y, Matsuo K, Yokoi K. Stepwise examination for differential diagnosis of primary lung cancer and breast cancer relapse presenting as a solitary pulmonary nodule in patients after mastectomy. J Surg Oncol 2008; 98 (7): 510–4.
5 Tanaka K, Shimizu K, Ohtaki Y et al. Diagnosis and surgical resection of solitary pulmonary nodules in patients with breast cancer. Mol Clin Oncol 2013; 1 (1): 117–23.
6 Kreisman H, Wolkove N, Finkelstein HS, Cohen C, Margolese R, Frank H. Breast cancer and thoracic metastases: Review of 119 patients. Thorax 1983; 38 (3): 175–9.
7 Chlebowski RT, Kuller LH, Prentice RL et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360 (6): 573–87.
8 Raymond J, Hogue CJ. Multiple primary tumours in women following breast cancer, 1973–2000. Br J Cancer 2006; 94 (11): 1745–50.
9 Diaz-Canton EA, Valero V, Rahman Z et al. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann Oncol 1998; 9 (4): 413–8.
10 Huang SW, Hsu CM, Jeng WJ, Yen TC, Su MY, Chiu CT. A comparison of positron emission tomography and colonoscopy for the detection of advanced colorectal neoplasms in subjects undergoing a health check-up. PloS One 2013; 8 (7): e69111.
11 Lin J, Kligerman S, Goel R, Sajedi P, Suntharalingam M, Chuong MD. State-of-the-art molecular imaging in esophageal cancer management: Implications for diagnosis, prognosis, and treatment. J Gastrointest Oncol 2015; 6 (1): 3–19.
12 Sun N, Zhao J, Qiao W, Wang T. Predictive value of interim PET/CT in DLBCL treated with R-CHOP: Meta-analysis. Biomed Res Int 2015; 2015: 648572.
13 Yu X, Li X, Song X et al. Advantages and disadvantages of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary. Oncol Lett 2016; 12 (5): 3785–92.
14 Yu X, Zhu Y, Wang J et al. Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer. Nucl Med Commun 2017; 38 (2): 193–200.
15 Bevers TB, Anderson BO, Bonaccio E et al. NCCN Clinical Practice Guidelines in Oncology: Breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009; 7 (10): 1060–96.
16 Gradishar WJ, Anderson BO, Balassanian R et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016; 14 (3): 324–54.
17 Evangelista L, Panunzio A, Cervino AR et al. Indeterminate pulmonary nodules on CT images in breast cancer patient: The additional value of 18F-FDG PET/CT. J Med Imaging Radiat Oncol 2012; 56 (4): 417–24.
18 Mion M, Chierichetti F, Liessi G et al. Diagnosis of recurrent breast cancer: 18F-FDG PET/CT as first choice. J Clin Oncol 2006; 24 (18_suppl): 10681.
19 Wood DE. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Lung Cancer Screening. Thorac Surg Clin 2015; 25 (2): 185–97.
20 Ettenger DS, Kris MG. Update: NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2004; 2 (Suppl 3): S9–13.
21 Ettenger D, Johnson B. Update: NCCN Small Cell And Non-Small Cell Lung Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005; 3 (Suppl 1): S17–21.
22 Kim TY, Lee KH, Han SW et al. A new isolated mediastinal lymph node or small pulmonary nodule arising during breast cancer surveillance following curative surgery: Clinical factors that differentiate malignant from benign lesions. Cancer Res Treat 2014; 46 (3): 280–7.
23 Kitada M, Sato K, Matsuda Y, Hayashi S, Miyokawa N, Sasajima T. Role of treatment for solitary pulmonary node in breast cancer patients. World J Surg Oncol 2011; 9: 124.
24 Quint LE, Park CH, Iannettoni MD. Solitary pulmonary nodules in patients with extrapulmonary neoplasms. Radiology 2000; 217 (1): 257–61.
25 Casey JJ, Stempel BG, Scanlon EF, Frye WA. The solitary pulmonary nodule in the patient with breast cancer. Surgery 1984; 96 (4): 801–5.
26 MacMahon H, Austin JH, Gamsu G et al. Guidelines for management of small pulmonary nodules detected on CT scans: A statement from the Fleischner Society. Radiology 2005; 237 (2): 395–400.
27 Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14 (8): 2197–205.
28 Yhimm HY, Han SW, Oh DY et al. Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. Cancer 2010; 116 (12): 2890–901.
29 Chan F, Fujinaga T, Sato K et al. Clinical features of surgical resection for pulmonary metastasis from breast cancer. Eur J Surg Oncol 2009; 35 (4): 393–7.
30 Yoshimoto M, Tada K, Nishimura S et al. Favourable long-term results after surgical removal of lung metastases of breast cancer. *Breast Cancer Res Treat* 2008; 110 (3): 485–91.
31 Nagayoshi Y, Yamamoto K, Hashimoto S et al. An autopsy case of lepidic pulmonary metastasis from cholangiocarcinoma. *Intern Med* 2016; 55 (19): 2849–53.
32 Khanfir A, Lahiani F, Bouzguenda R, Ayedi I, Daoud J, Frikha M. Prognostic factors and survival in metastatic breast cancer: A single institution experience. *Rep Pract Oncol Radiother* 2013; 18 (3): 127–32.
33 Villaruz LC, Kubicek GJ, Socinski MA. Management of non-small cell lung cancer with oligometastasis. *Curr Oncol Rep* 2012; 14 (4): 333–41.
34 Lee JW, Kim BS, Lee DS et al. 18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: Consideration of lymph node calcification and distribution pattern to improve specificity. *Eur J Nucl Med Mol Imaging* 2009; 36 (11): 1794–802.
35 Lu P, Sun Y, Sun Y, Yu L. The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma. *Lung Cancer* 2014; 85 (1): 53–8.
36 Li X, Zhang H, Xing L et al. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: A multicenter study. *Radiother Oncol* 2012; 102 (2): 246–50.
37 Darling GE, Maziak DE, Inculet RI et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: Results of mediastinal staging in the early lung positron emission tomography trial. *J Thorac Oncol* 2011; 6 (8): 1367–72.
38 Lee AY, Choi SJ, Jung KP, Park JS, Lee SM, Bae SK. Characteristics of metastatic mediastinal lymph nodes of non-small cell lung cancer on preoperative F-18 FDG PET/CT. *Nucl Med Mol Imaging* 2014; 48 (1): 41–6.
39 Ye Z, Zhang X, Luo Y et al. Prognostic values of vimentin expression and its clinicopathological significance in non-small cell lung cancer: A meta-analysis of observational studies with 4118 cases. *PloS One* 2016; 11 (9): e0163162.